Sweet syndrome in a patient receiving encorafenib and binimetinib therapy for malignant melanoma
Saved in:
Main Authors: | Myiah Quach, BS (Author), John P. Antonelli, BS (Author), Charlotte LaSenna, MD (Author), Mackenzie Asel, MD (Author), Jennifer Pleva, DNP (Author), Vincent T. Ma, MD (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database
by: Shuang Xia, et al.
Published: (2024) -
Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report
by: Karen Lam, et al.
Published: (2024) -
Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia
by: N. A. Avxentyev, et al.
Published: (2023) -
Two cases of acute‐onset cystoid macular edema and serous retinal detachment associated with combined use of encorafenib and binimetinib for advanced melanoma: A possible confounding risk for drug intolerance
by: Takumi Hasegawa, et al.
Published: (2023) -
Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome
by: Peter A. Young, MPAS, BS, et al.
Published: (2021)